Effectiveness of Bio-K+ for the prevention of Clostridioides difficile infection: Stepped-wedge cluster-randomized controlled trial

Jenine Leal, Ye Shen, Peter Faris, Bruce Dalton, Deana Sabuda, Wrechelle Ocampo, Lauren Bresee, Blanda Chow, Jared R. Fletcher, Elizabeth Henderson, Jaime Kaufman, Joseph Kim, Maitreyi Raman, Scott Kraft, Nicole C. Lamont, Oscar Larios, Bayan Missaghi, Jayna Holroyd-Leduc, Thomas Louie, John Conly
{"title":"Effectiveness of Bio-K+ for the prevention of Clostridioides difficile infection: Stepped-wedge cluster-randomized controlled trial","authors":"Jenine Leal, Ye Shen, Peter Faris, Bruce Dalton, Deana Sabuda, Wrechelle Ocampo, Lauren Bresee, Blanda Chow, Jared R. Fletcher, Elizabeth Henderson, Jaime Kaufman, Joseph Kim, Maitreyi Raman, Scott Kraft, Nicole C. Lamont, Oscar Larios, Bayan Missaghi, Jayna Holroyd-Leduc, Thomas Louie, John Conly","doi":"10.1017/ice.2023.169","DOIUrl":null,"url":null,"abstract":"<span>Objective:</span><p>To evaluate the impact of administering probiotics to prevent <span>Clostridioides difficile</span> infection (CDI) among patients receiving therapeutic antibiotics.</p><span>Design:</span><p>Stepped-wedge cluster-randomized trial between September 1, 2016, and August 31, 2019.</p><span>Setting:</span><p>This study was conducted in 4 acute-care hospitals across an integrated health region.</p><span>Patients:</span><p>Hospitalized patients, aged ≥55 years.</p><span>Methods:</span><p>Patients were given 2 probiotic capsules daily (Bio-K+, Laval, Quebec, Canada), containing 50 billion colony-forming units of <span>Lactobacillus acidophilus</span> CL1285, <span>L. casei</span> LBC80R, and <span>L. rhamnosus</span> CLR2. We measured hospital-acquired CDI (HA-CDI) and the number of positive <span>C. difficile</span> tests per 10,000 patient days as well as adherence to administration of Bio-K+ within 48 and 72 hours of antibiotic administration. Mixed-effects generalized linear models, adjusted for influenza admissions and facility characteristics, were used to evaluate the impact of the intervention on outcomes.</p><span>Results:</span><p>Overall adherence of Bio-K+ administration ranged from 76.9% to 84.6% when stratified by facility and periods. Rates of adherence to administration within 48 and 72 hours of antibiotic treatment were 60.2% –71.4% and 66.7%–75.8%, respectively. In the adjusted analysis, there was no change in HA-CDI (incidence rate ratio [IRR], 0.92; 95% confidence interval [CI], 0.68–1.23) or <span>C. difficile</span> positivity rate (IRR, 1.05; 95% CI, 0.89–1.24). Discharged patients may not have received a complete course of Bio-K+. Our hospitals had a low baseline incidence of HA-CDI. Patients who did not receive Bio-K+ may have differential risks of acquiring CDI, introducing selection bias.</p><span>Conclusions:</span><p>Hospitals considering probiotics as a primary prevention strategy should consider the baseline incidence of HA-CDI in their population and timing of probiotics relative to the start of antimicrobial administration.</p>","PeriodicalId":13558,"journal":{"name":"Infection Control & Hospital Epidemiology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection Control & Hospital Epidemiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/ice.2023.169","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective:

To evaluate the impact of administering probiotics to prevent Clostridioides difficile infection (CDI) among patients receiving therapeutic antibiotics.

Design:

Stepped-wedge cluster-randomized trial between September 1, 2016, and August 31, 2019.

Setting:

This study was conducted in 4 acute-care hospitals across an integrated health region.

Patients:

Hospitalized patients, aged ≥55 years.

Methods:

Patients were given 2 probiotic capsules daily (Bio-K+, Laval, Quebec, Canada), containing 50 billion colony-forming units of Lactobacillus acidophilus CL1285, L. casei LBC80R, and L. rhamnosus CLR2. We measured hospital-acquired CDI (HA-CDI) and the number of positive C. difficile tests per 10,000 patient days as well as adherence to administration of Bio-K+ within 48 and 72 hours of antibiotic administration. Mixed-effects generalized linear models, adjusted for influenza admissions and facility characteristics, were used to evaluate the impact of the intervention on outcomes.

Results:

Overall adherence of Bio-K+ administration ranged from 76.9% to 84.6% when stratified by facility and periods. Rates of adherence to administration within 48 and 72 hours of antibiotic treatment were 60.2% –71.4% and 66.7%–75.8%, respectively. In the adjusted analysis, there was no change in HA-CDI (incidence rate ratio [IRR], 0.92; 95% confidence interval [CI], 0.68–1.23) or C. difficile positivity rate (IRR, 1.05; 95% CI, 0.89–1.24). Discharged patients may not have received a complete course of Bio-K+. Our hospitals had a low baseline incidence of HA-CDI. Patients who did not receive Bio-K+ may have differential risks of acquiring CDI, introducing selection bias.

Conclusions:

Hospitals considering probiotics as a primary prevention strategy should consider the baseline incidence of HA-CDI in their population and timing of probiotics relative to the start of antimicrobial administration.

Bio-K+ 预防艰难梭菌感染的效果:阶梯式群组随机对照试验
目的:评估在接受治疗性抗生素的患者中使用益生菌预防艰难梭菌感染(CDI)的影响。设计:2016年9月1日至2019年8月31日期间进行的阶梯式分组随机试验。方法:患者每天服用2粒益生菌胶囊(Bio-K+,加拿大魁北克省拉瓦尔市),其中含有500亿菌落形成单位的嗜酸乳杆菌CL1285、干酪乳杆菌LBC80R和鼠李糖乳杆菌CLR2。我们测量了医院获得性 CDI(HA-CDI)和每 10,000 个患者日艰难梭菌检测阳性的数量,以及在使用抗生素 48 小时和 72 小时内服用 Bio-K+ 的依从性。在对流感入院人数和设施特征进行调整后,采用混合效应广义线性模型来评估干预措施对结果的影响。结果:按设施和时间分层后,Bio-K+用药的总体依从性从76.9%到84.6%不等。在抗生素治疗后 48 小时和 72 小时内坚持用药的比例分别为 60.2% -71.4% 和 66.7% -75.8%。在调整后的分析中,HA-CDI(发病率比 [IRR],0.92;95% 置信区间 [CI],0.68-1.23)或艰难梭菌阳性率(IRR,1.05;95% 置信区间 [CI],0.89-1.24)没有变化。出院患者可能未接受完整疗程的 Bio-K+。我们医院的 HA-CDI 基线发病率较低。结论:考虑将益生菌作为一级预防策略的医院应考虑其人群中HA-CDI的基线发病率以及相对于开始使用抗菌药物的益生菌使用时机。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信